Metabolomics reveals sex-specific metabolic shifts and predicts the duration from positive to negative in non-severe COVID-19 patients during recovery process

Hong Zheng a,b, Shengwei Jin c, Ting Li d, Weiyang Ying e, Binyu Ying f, Dong Chen g, Jie Ning b, Chanfan Zheng d, Yuping Li a, Chen Li b, Chengshui Chen a, Xiaokun Li b,e, Hongchang Gao a,b,*

a Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, China
b School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
c Department of Anesthesia and Critical Care, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China
d Clinical Research Unit, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, China
e Department of Pain Medicine, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China
f Department of Critical Care Medicine, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China
g Wenzhou Central Hospital, Wenzhou 325015, China

A R T I C L E   I N F O

Article history:
Received 19 February 2021
Received in revised form 29 March 2021
Accepted 31 March 2021
Available online 06 April 2021

Keywords:
COVID-19
SARS-CoV
Metabolism
Sex difference
Fatty acid

A B S T R A C T

Metabolic profiling in COVID-19 patients has been associated with disease severity, but there is no report on sex-specific metabolic changes in discharged survivors. Herein we used an integrated approach of LC-MS and GC–MS-based untargeted metabolomics to analyze plasma metabolic characteristics in men and women with non-severe COVID-19 at both acute period and 30 days after discharge. The results demonstrate that metabolic alterations in plasma of COVID-19 patients during the recovery and rehabilitation process were presented in a sex-specific manner. Overall, the levels of most metabolites were increased in COVID-19 patients after the cure relative to acute period. The major plasma metabolic changes were identified including fatty acids in men and glycerophosphocholines and carbohydrates in women. In addition, we found that women had shorter length of hospitalization than men and metabolic characteristics may contribute to predict the duration from positive to negative in non-severe COVID-19 patients. Collectively, this study shed light on sex-specific metabolic shifts in non-severe COVID-19 patients during the recovery process, suggesting a sex bias in prognostic and therapeutic evaluations based on metabolic profiling.

© 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The novel coronavirus disease 2019 (COVID-19) broke out in December 2019 due to SARS-CoV-2 and is rapidly spreading around the world. As of November 24, 2020, over 59 million subjects have been infected worldwide, causing over 1 million deaths. COVID-19 is initially characterized by inflammatory syndrome such as fever, fatigue, cough, and muscle pain [1]. Yet, no effective treatments are available to date except comprehensive support. Therefore, some patients will develop to severe symptoms including acute respiratory distress, septic shock, metabolic acidosis, and even organ failure, leading to increased mortality. Scientists and medical staffs around the world are still working to discover a cure for COVID-19.

At the beginning, most studies on COVID-19 focused on its epidemiological and clinical characteristics [2–5]. Later, researchers started to be concerned about the diagnosis [6–9] and treatment [10–12] of COVID-19. Omics technique as a systems biology approach attempts to dissect the pathophysiological complexities of human diseases [13] and has also been used to explore the

References:
[1] Hong Chang Gao, Hongchang Gaoa,b, Shengwei Jin c, Ting Li d, Weiyang Ying e, Binyu Ying f, Dong Chen g, Jie Ning b, Chanfan Zheng d, Yuping Li a, Chen Li b, Chengshui Chen a, Xiaokun Li b,e, Hongchang Gao a,b,*

a Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, China
b School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
c Department of Anesthesia and Critical Care, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China
d Clinical Research Unit, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, China
e Department of Pain Medicine, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China
f Department of Critical Care Medicine, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China
g Wenzhou Central Hospital, Wenzhou 325015, China
pathogenesis and diagnostic markers of COVID-19. For example, using lipidomics and metabolomics, Song et al. revealed that GM3-enriched exosomes are positively associated with COVID-19 pathogenesis and a panel of 10 plasma metabolites can distinguish COVID-19 patients from healthy controls with an AUC value of 0.975 [14]. In addition, Shen et al. identified 93 proteins and 204 metabolites in serum that correlate with the severity of COVID-19 and uncovered metabolic and immune dysregulation in COVID-19 patients through an integrated method of proteomics and metabolomics [15]. These two studies focused on multi-omics characteristics during the onset and progression of COVID-19, but understanding metabolic alterations during the recovery and rehabilitation process is also of great importance [16]. However, so far information regarding this aspect is not available. Interestingly, the sex effect on COVID-19 is also drawing public attention, and male patients have more severe disease and higher mortality than female patients [17–19]. Takahashi et al. reported that sex differences in immune response may cause disparities in outcomes of COVID-19 between two genders, providing an important basis for developing sex-based strategies for the treatment and care of COVID-19 [20]. Thus, it is of great interest to elucidate sex-specific metabolic changes during recovery from COVID-19.

In this study, we retrospectively recruited a cohort of patients with non-severe COVID-19 including 20 male and 20 female at both acute period and 30 days after discharge. Plasma metabolic profiling was analyzed by using an integrated method of LC-MS- and GC–MS-based untargeted metabolomics. The aims of this study were (1) to identify sex-specific metabolic changes in discharged survivors, (2) to analyze correlations between metabolites and clinical parameters, and (3) to predict the duration from positive to negative in non-severe COVID-19 using metabolic profiling.

2. Materials and methods

2.1. Patients and sampling

We retrospectively recruited a total of 40 COVID-19 patients including 20 male and 20 female at the Second Affiliated Hospital of Wenzhou Medical University from February 23 to March 07, 2020. According to the Chinese government diagnosis and treatment guideline (Trial 5th version, NHCP, 2020), patients were diagnosed as COVID-19 when they met the following criteria: 1) fever, dry cough or respiratory symptoms; 2) positive for SARS-CoV-2 nucleic acid; 3) imaging manifestation of pneumonia. Moreover, these patients were scheduled for follow-up visit at 30 days after discharge. Demographic and clinical data of COVID-19 patients were obtained from electronic medical records as shown in Tables 1, S1 and S2. All blood samples were collected in the morning and transferred to the clinical laboratory using a biosafety transport box. Plasma samples were separated by centrifuging at 1,500 g for 15 min, collected into new tubes and immediately stored at −80 °C. This study was approved by the Ethical Committee of Wenzhou Medical University (ID: 2020–025), and written informed consents were acquired from all subjects after discharge. All procedures in this study were carried out according to the 2008 Helsinki Declaration and the clinical-ethical guidelines of the Second Affiliated Hospital of Wenzhou Medical University.

2.2. Sample preparation

All plasma samples were inactivated and sterilized at 56 °C for 30 min. An aliquot of 100 μL sample was added to a 1.5 mL centrifuge tube and mixed with 10 μL of L-2-chlorophenylalanine (0.3 mg/mL) and LysoPC17:0 (0.01 mg/mL) prepared in methanol as internal standards, and the mixture was vortexed for 10 s. Then, 300 μL of ice-cold mixture of methanol and acetonitrile (v:v = 2:1) was added and vortexed for 1 min, ultrasonicated at 0 °C for 10 min, and stood at −20 °C for 30 min. The extract was centrifuged at 13,000 rpm for 15 min at 4 °C, and the supernatant was transferred into a new centrifuge tube and dried using a freeze concentration centrifugal dryer. The lyophilized powder was redisolved in 100 μL mixed solution of methanol and water (v:v = 1:4), vortexed for 30 s, and then placed at 4 °C for 2 min. Then, the mixture was centrifuged at 13,000 rpm for 5 min at 4 °C, and the supernatant was transferred to a glass sampling vial for vacuum dry at 25 °C, and mixed with 80 μL of methoxylamine hydrochloride prepared in pyridine (15 mg/mL). The mixture was vigorously vortexed for 2 min and incubated at 37 °C for 90 min. Subsequently, 80 μL of BSTFA (with 1% TMCS) and 20 μL of n-hexane was added, vortexed for 2 min and then derivatized at 70 °C for 60 min. The sample was placed at 25 °C for 30 min for GC–MS analysis. The quality control (QC) sample was prepared by mixing aliquots of all samples.

2.3. LC-MS-based untargeted metabolomics analysis

Plasma metabolic profiling was acquired by an ACQUITY UHPLC system (Waters Corporation Milford, USA) coupled with AB SCIEX Triple TOF 5600 System (AB SCIEX, Framingham, MA) under both ESI positive and negative ion modes. A Waters BEH C18 column (1.7 μm, 2.1 × 100 mm) was used and the mobile phase consisted of acetonitrile and water containing 0.1% formic acid. In addition, the following parameters were set: flow rate, 0.4 mL/min; column temperature, 45 °C; injection volume, 1 μL. Data acquisition was carried out in full scan mode from 70 to 1000 m/z and the IDA mode with m/z range of 25–1000 and collision energy of 30 eV. The QC samples were injected every 10 runs for evaluation of data repeatability.

The LC-MS raw data were analyzed by Progenesis QI software (Waters Corporation, Milford, USA) with the following parameters: precursor tolerance, 5 ppm; fragment tolerance, 10 ppm; retention time (RT) tolerance, 0.02 min; noise elimination level, 10.00. Moreover, isotopic peaks were removed for data analysis and minimum intensity was set to 15% of base peak intensity. Metabolites were identified using HMDB (https://hmdb.ca/), LIPID MAPS (https://lipidmaps.org/) and self-built databases according to RT–m/z pairs and tandem mass spectrometry (MS/MS) spectra. Then, the data matrix was outputted as the Excel file with three dimension datasets including m/z, peak RT and intensities for further analysis.

2.4. GC–MS-based untargeted metabolomics analysis

Metabolic profiling of the derivative sample was analyzed by using an Agilent 7890B gas chromatography system (Agilent Technologies Inc., CA, USA) equipped with a DB-5MS fused-silica capillary column (30 m × 0.25 mm × 0.25 μm) at a constant helium flow rate of 1 mL/min. The parameters of GC–MS condition were set as follows: injector temperature, 260 °C; injection volume, 1 μL; MS quadrupole temperature, 150 °C; ion source temperature, 230 °C; collision energy, 70 eV; mass range, 50–500 m/z. The QC samples were injected every 10 runs for data quality control.

The raw data of GC–MS analysis were converted to ABF format via the Analysis Base File Converter software, and then imported into the MS-DIAL software for peak detection, deconvolution, alignment, and filtering. Metabolites were identified in the basis of the LUG database (Untargeted database of GC–MS from Lumingbio). All internal standards and pseudo positive peaks were
removed and then the data matrix with three dimension datasets including sample information, peak names and intensities was exported as the Excel file with for further analysis.

2.5. Statistical analysis

In the present study, we selected metabolite peaks with coefficients of variations (CV) < 15% across nine QC samples for further analysis. To examine changes in metabolic patterns between different groups, partial least squares-discriminant analysis (PLS-DA) was carried out using Pareto-scaled data in SIMCA 12.0 software (UMetrics, Umeå, Sweden). Moreover, partial least squares regression (PLSR) was used to predict the duration from positive to negative in non-severe COVID-19 patients based on clinical parameters or metabolomics data in SIMCA 12.0 software. In this study, we used 10-fold cross validation (10-CV) to evaluate the performances of PLS-DA and PLSR. The number of latent variables (LV) was set to 2 for both PLS-DA and PLSR. For PLS-DA, R² and Q² values were calculated to indicate goodness-of-fit and predictive capability, respectively. For PLSR, linear regression analysis was performed to assess the agreement between predicted and observed values. Important metabolites were identified by the variable importance in the projection (VIP) method, where metabolites with VIP values > 1.0 were selected for further analysis. The difference in metabolite level between two groups was analyzed using paired-samples t-tests with the Bonferroni correction using SPSS software (version 13.0; SPSS Inc., Chicago, IL, USA) and considered to be statistically significant when p < 0.05. The relationship between metabolic data and clinical parameters was analyzed by Spearman’s correlation in MATLAB (R2012a, the MathWorks, Inc., MA, USA) and illustrated as heatmaps.

3. Results

3.1. Metabolomics profiling in plasma of non-severe COVID-19 patients

We collected plasma samples from a cohort of patients with non-severe COVID-19 including 20 male and 20 female at both acute period and 30 days after discharge (Fig. 1a), and their detailed clinical characteristics are shown in Tables 1, S1 and S2. The results reveal that the main symptoms of COVID-19 included fever, dry cough, expectoration, weak and sore throat, and there were no significant differences between two genders (Table 1). Of note, after infecting with SARS-CoV-2, male might have a higher proportion of dry cough than female (60% vs. 30%, P = 0.111). In addition, we observed significantly higher levels of C-reactive protein (P = 0.018), hemoglobin (P < 0.001), alanine aminotransferase (P = 0.044), total bilirubin (P < 0.001), carbamide (P = 0.024), and serum creatinine (P = 0.005) in male patients with COVID-19 at

Fig. 1. Plasma metabolomics analysis of COVID-19 patients. (a) Plasma samples were collected from patients with non-severe COVID-19 including 20 male and 20 female at both acute period and 30 days after discharge for both LC-MS-and GC–MS untargeted metabolomics analysis. The differences of metabolic phenotypes in plasma between COVID-19 patients at acute period (AP) and follow-up period (FP) analyzed by PLS-DA using LC-MS-based (b, men; c, women) and GC–MS-based (d, men; e, women) metabolic profiling. Subsequently, metabolites with VIP > 1.0 were selected and volcano plot analysis was used to identify important metabolites (p < 0.05) as highlighted in Fig. 1b-1e. (f) Venn diagram analysis based on the selected important metabolites, showing that there were 33 common metabolites in both male and female patients, and 31 and 27 metabolites were identified as unique metabolites in male and female patients, respectively.
The results demonstrate that clear separations were obtained between AP and FP in both male (Fig. 1b and 1d) and female (Fig. 1c and 1e) patients, suggesting that the metabolic phenotypes of non-severe COVID-19 patients were significantly altered after the cure. Subsequently, metabolites with VIP > 1.0 were selected and volcano plot analysis was used to identify important metabolites as highlighted in Fig. 1b-1e, where we found that the levels of most metabolites were significantly lower in AP relative to FP, indicating a hypometabolic state in COVID-19 patients. Venn diagram analysis shows that there were 33 common important metabolites in two genders, and 31 and 27 metabolites were identified as unique important metabolites in male and female patients, respectively (Fig. 1f).

We found that the levels of most metabolites were increased in plasma of both male and female patients with non-severe COVID-19 from AP to FP (Figure S2), indicating a higher metabolic activity after the cure. Shen et al. have reported that COVID-19 patients displayed a massive metabolic suppression relative to controls [15]. Thus, our data suggest that improving metabolic activity could be conducive to the recovery of COVID-19. However, sphingoid bases, such as C16 sphinganine and xestoaminol C, were significantly reduced in COVID-19 patients after healing. Sphingoid bases have been revealed to affect the resistance of rat renal and mesenteric vessels through G protein-coupled receptor [21] and exhibit cytotoxic activity [22]. A decreased level of tryptophan was observed in both serum [23] and plasma [14] of COVID-19 patients, but here we did not detect an increased tryptophan level after treatment. Oxoproline, an important mediator of oxidative stress [24], was reduced in COVID-19 patients after the cure. In addition, we also found decreased levels of glucose, 2-hydroxynonenal, trans-cinnamic acid and 3-acrylamidopropyl trimethylammonium in COVID-19 patients from AP to FP (Figure S2).

In male patients with non-severe COVID-19, several long-chain fatty acids (LCFAs), such as 22-hydroxydocosanoic acid, 20-hydroxy-eicosanoic acid, (+)-14-methyl palmitic acid and 13,14-dihydroxy-docosanoic acid, were significantly reduced after discharge, while 8-methoxy-13-hydroxy-9,11-octadecadienoic acid, 7,10-hexadecadiynoic acid, cericin acid B and 9,10-DHOME were raised (Fig. 2a). Increased LCFAs have been identified in serum of COVID-19 patients by Thomas et al. [23]. Therefore, we speculate that lowering LCFAs level may be helpful for treating COVID-19, but specific LCFAs need to be identified. Moreover, we found that two carnitines (decanoylcarnitine and O-octanoyl-R-carnitine) were elevated after treatment. Carnitines have been reported to suppress inflammation [25] and oxidative stress [26] and protect against lung injury [27]. Coronavirus infection can trigger ER stress and subsequent eicosanoid and cytokine storms, and then cause tissue injury [28]. Targeting eicosanoids could be a therapeutic strategy for COVID-19 [28]. In the present study, yet, the levels of eicosanoids such as PGF1α alcohol and PGE1 alcohol were observed to be significantly increased in male patients after treatment. Besides, we detected lower levels of 17-hydroxy stearic acid, phytophthora mating hormone alpha1, pristaneic acid, 7,α-hydroxy-3-oxo-5beta-cholan-24-oic acid, MG(18:1(9Z)/0:0/0:0), indinavir and sphinganine as well as higher levels of 21-methyl-8Z-pentatriacontene, tetrahydrodeoxycortisol, 4-hydroxyproline, methyl beta-d-glucopyranoside, glycerol, kamahine C, 4-hydroxy-3-oxo-5beta-cholan-24-oic acid, MG(18:1(9Z)/0:0/0:0), indinavir and sphinganine as well as higher levels of 21-methyl-8Z-pentatriacontene, tetrahydrodeoxycortisol, 4-hydroxyproline, methyl beta-d-glucopyranoside, glycerol, kamahine C, 4-hydroxy-

Table 1 Demographics and baseline characteristics of COVID-19 patients.

| Characteristics          | Male (n = 20) | Female (n = 20) | P       |
|--------------------------|--------------|----------------|---------|
| Age (year)               | 47.70 ± 14.41| 48.90 ± 10.92  | 0.768   |
| BMI (kg/m²)              | 24.89 ± 2.16 | 22.32 ± 3.36   | 0.007   |
| Heart rate               | 81.60 ± 14.74| 82.10 ± 12.19  | 0.908   |
| Respiration rate         | 19.75 ± 0.91 | 21.20 ± 9.21   | 0.488   |
| Systolic blood pressure  | 129.70 ± 15.55| 132.10 ± 11.50 | 0.590   |
| Diastolic blood pressure | 80.90 ± 11.61| 84.40 ± 10.32  | 0.321   |
| Fever                    | 16 (80%)     | 13 (65%)       | 0.480   |
| Dry cough                | 12 (60%)     | 6 (30%)        | 0.111   |
| Expectoration            | 10 (50%)     | 12 (60%)       | 0.751   |
| Weak                     | 7 (35%)      | 6 (30%)        | 1.000   |
| Sore throat              | 6 (30%)      | 6 (30%)        | 1.000   |
| Anorexia                 | 2 (10%)      | 5 (25%)        | 0.407   |
| Diarrhea                 | 5 (25%)      | 3 (15%)        | 0.695   |
| Nasal congestion         | 2 (10%)      | 4 (20%)        | 0.661   |
| Myalgia                  | 3 (15%)      | 4 (20%)        | 1.000   |
| Nausea                   | 3 (15%)      | 4 (20%)        | 1.000   |
| Headache                 | 1 (5%)       | 4 (20%)        | 0.342   |
| Stomachache              | 0 (0%)       | 1 (5%)         | 1.000   |
| Dipsnea                  | 1 (5%)       | 0 (0%)         | 1.000   |
| Treatment time (day)     | 24.00 ± 5.98 | 20.40 ± 7.05   | 0.090   |

* Antiviral drugs mainly included arbidol hydrochloride granules, recombinant human interferon alfa-2b, lopinavir/ritonavir, indinavir and ribavirin; Antibiotics mainly included methylprednisolone.

3.2. Sex-specific metabolic changes in plasma of non-severe COVID-19 patients

To examine sex-specific metabolic changes in plasma of non-severe COVID-19 patients between acute period (AP) and follow-up period (FP), PLS-DA model was performed using metabo-
PC(0-16:0/3:0), PC(P-15:0/0:0) and PC(0-16:0/4:0) as well as decreased levels of PC(18:3(9Z,12Z,15Z))/0:0, PC(18:3 (6Z,9Z,12Z)/0:0) and LysoPC(18:3(9Z,12Z,15Z)). GPCs-related metabolites have been reported to modulate systemic oxidative stress and inflammation, but it should be noting that different structures may result in functional differences [29–31]. Thus, regulation of specific GPCs would be beneficial to treat COVID-19 especially in female patients. Cheudjeu suggested D-xylene as a possible therapeutic use for COVID-19 due to its anti-inflammatory and antiviral properties in lung infections [32]. However, our data show a reduced level of D-xylene in plasma of female COVID-19 patients after discharge. Interestingly, we found that the levels of alpha-d-glucose, 1-kestose, D-ribose and D-mannose were significantly increased after treatment. D-ribose has been reported to be an energy enhancer for maintaining mitochondrial functions [33], but it can also promote the production of advanced glycation end products (AGEs) and cause severe cytotoxicity [34]. Of note, D-mannose can alleviate immunopathology by increasing the proportion of regulatory T cells [35]; therefore, we suggest that D-mannose might have a potential therapeutic effect on COVID-19. Sphingosine-1-phosphate (S1P) as a key cell signaling molecule [36] was significantly increased in female patients after the cure, which is in agreement with the finding of Song et al. that the level of S1P was reduced in COVID-19 patients but increased after discharge. O f note, our results reveal that a higher level of dehydroascorbic acid (DAA) was linked with decreased NG in female patients, suggesting the protective function of DAA on COVID-19. One possible explanation for this finding is that DAA can be metabolized to ascorbic acid, and thereby exerts a vitamin activity on neutrophils and inflammation [41,42]. Lymphocyte (LY) as one of WBCs was positively correlated with D-xylose and 6,7-dimethyl-4-hydroxy-2-pteridinamine (Fig. 3b). NG is the highly abundant myeloid cell type in humans, accounting for 40% to 70% of total WBC, and plays an important role in inflammatory response [39]. In COVID-19 patients, granulocytic makers including NG were enriched and used to discriminate between mild and severe patients [40]. Of note, our results reveal that a higher level of dehydroascorbic acid (DAA) was linked with decreased NG in female patients, suggesting a protective effect of DAA on COVID-19. One possible explanation for this finding is that DAA can be metabolized to ascorbic acid, and thereby exerts a vitamin activity on neutrophils and inflammation [41,42]. Lymphocyte (LY) as one of WBCs was positively correlated with leucine. The reduction in LY has been associated with the severity of COVID-19 [14,15]. Here we suggest that increased leucine might be helpful to treat COVID-19 via LY activation [43]. In female patients, ALT was found to be positively and negatively correlated with 3-heptynoic acid (DAA) and D-daunorubicin, respectively (Fig. 3b). Hence, a lower level of S1P in COVID-19 patients may indicate a higher ALT, suggesting an impaired liver and kidney functions in COVID-19 patients [14]. S1P has been revealed to promote the resolution of inflammation through activating macrophages [44,45]. Glycerophospholipids are also involved in inflammatory response [46,47]. Here we found that C-reactive protein (CRP) was negatively linked with PC(18:3 (6Z,9Z,12Z)/0:0) and LysoPC(18:3(9Z,12Z,15Z)) (Fig. 3b). Moreover, PC(18:3(6Z,9Z,12Z)/0:0) was positively correlated with the level of K and negatively correlated with D-dimer (DD). Lower levels of PC with red cell distribution width (RDW) and white blood cell (WBC), suggesting that a high level of MG(18:1(9Z)/0:0/0:0) may disrupt blood cell homeostasis and cause an adverse effect on COVID-19. Tetrahydrodesoxy cortisol (THS) is derived from cortisol metabolism as a regulator of glucocorticoid action in liver and kidney [37,38]. For this reason, a negative relationship between THS and alanine aminotransferase (ALT) indicates that glucocorticoid might be an effective drug for improving the liver and kidney functions in COVID-19 patients. In addition, we found that carbamide (CA) was positively correlated with (+)-14-methyl palmitic acid, isopropyl tetradecanoate and pristanic acid (Fig. 3a). A positive relationship was also observed between activated partial thromboplastin time (APTT) and pristanic acid as well as between the level of Na and 4-hydroxyproline in male patients.

In female patients with non-severe COVID-19, we found that WBC and neutrophilic granulocyte (NG) were significantly and positively correlated with D-xylene and 6,7-dimethyl-4-hydroxy-2-pteridinamine (Fig. 3b). NG is the highly abundant myeloid cell type in humans, accounting for 40% to 70% of total WBC, and plays an important role in inflammatory response [39]. In COVID-19 patients, granulocytic makers including NG were enriched and used to discriminate between mild and severe patients [40]. Of note, our results reveal that a higher level of dehydroascorbic acid (DAA) was linked with decreased NG in female patients, suggesting a protective effect of DAA on COVID-19. One possible explanation for this finding is that DAA can be metabolized to ascorbic acid, and thereby exerts a vitamin activity on neutrophils and inflammation [41,42]. Lymphocyte (LY) as one of WBCs was positively correlated with leucine. The reduction in LY has been associated with the severity of COVID-19 [14,15]. Here we suggest that increased leucine might be helpful to treat COVID-19 via LY activation [43]. In female patients, ALT was found to be positively and negatively correlated with 3-heptynoic acid (DAA) and D-daunorubicin, respectively (Fig. 3b). Hence, a lower level of S1P in COVID-19 patients may indicate a higher ALT, suggesting an impaired liver and kidney functions in COVID-19 patients [14]. S1P has been revealed to promote the resolution of inflammation through activating macrophages [44,45]. Glycerophospholipids are also involved in inflammatory response [46,47]. Here we found that C-reactive protein (CRP) was negatively linked with PC(18:3 (6Z,9Z,12Z)/0:0) and LysoPC(18:3(9Z,12Z,15Z)) (Fig. 3b). Moreover, PC(18:3(6Z,9Z,12Z)/0:0) was positively correlated with the level of K and negatively correlated with D-dimer (DD). Lower levels of PC
and 11-deoxy-PGF1b were associated with higher level of Cl (Fig. 3b). Coumarin-SAHA was positively related with hemoglobin (HGB) and red cell distribution width (RDW). Moreover, positive relationships were also obtained between leucine and CA as well as between 3-heptynoic acid and fibrinogen (FIB).

The associations between metabolites and lymphocyte subtypes after discharge were analyzed in male and female patients as shown in Fig. 3a and 3b, respectively. Ni et al. reported that a reduction of T lymphocytes was a common symptom in patients with severe COVID-19 [48]. After treatment, CD4+ and CD8+ T lymphocytes were significantly increased, but no significant changes were obtained in B lymphocytes and natural killer (NK) cells [48]. In the present study, the percentage of total T lymphocyte (TTL%) shows a positive correlation with 7,10-hexadecadiynoic acid and negative correlations with decanoyl carnitine and 8-methoxy-13-hydroxy-9,11-octadecadienoic acid in male patients. However, the percentage of total B lymphocyte (TBL%) was positively linked with 17-hydroxy stearic acid and 7alpha-hydroxy-3-oxo-5beta-cholan-24-oic acid. Fatty acids have been reported to influence lymphocytes [49,50] and inflammation [51,52] through multiple mechanisms; therefore, regulation of specific fatty acid metabolism may improve COVID-19-induced disturbance of lymphocytes. Besides, CD8% was negatively related with 8-methoxy-13-hydroxy-9,11-octadecadienoic acid and PGF1α alcohol. A positive relationship was obtained between CD4/CD8 and methyl beta-d-glucopyranoside (Fig. 3a). NK cells play a key role in regulating the immune response in the body, and a significantly reduced number of NK cells were detected in COVID-19 patients [53–55]. In female patients, interestingly, carbohydrates including alpha-d-glucose, 1-ketose, D-ribose and D-mannose were positively correlated with TNK and NK% (Fig. 3b). Carbohydrates as T cell-activating antigens have been attracting great interest [56]. For example, carbohydrate consumption has been shown to increase the number and activity of NK cells [57–59]. TBL displayed positive correlations with glycerophospholipids, including PC(18:3(9Z,12Z,15Z)/0:0) and PC(18:3(6Z,9Z,12Z)/0:0). Moreover, a positive relationship was also found between CD8% and Anandamide (20:1, n-9) in female patients (Fig. 3b).

Lung injury is a typical characteristic in COVID-19 patients, so concerns have been raised about the evaluation of lung functions in discharged patients [60,61]. In the present study, the correlation heatmap between metabolites and lung functions were analyzed in male (Fig. 3a) and female (Fig. 3b) patients after discharge. The results demonstrate that pulmonary functions were positively correlated with fatty acids, including 22-hydroxydocosanoic acid, 20-hydroxy-eicosanoic acid and 13,14-dihydroxy-docosanoic acid in male patients (Fig. 3a). Higher levels of glycerol and bile acid (7alpha-hydroxy-3-oxo-5beta-cho lan-24-oic acid) were related with improved pulmonary functions of male patients (Fig. 3a). A positive relationship was also found between dysthrose in female patients (Fig. 3b).

Fig. 3. Correlation heatmap between plasma metabolites and clinical parameters. The relationships between metabolites and blood chemical parameters, lymphocyte subtypes and lung function parameters in male (a) and female (b) patients with non-severe COVID-19. Spearman correlation analysis was carried out to assess the associations between metabolic changes and clinical parameters, and only correlations with |R|>0.5 and p < 0.05 were highlighted in Fig. 3.
3.4. Prediction of the duration from positive to negative in non-severe COVID-19 patients using clinical parameters and metabolic data

We then used PLSR to predict the duration from positive to negative in non-severe COVID-19 patients using clinical parameters and metabolic data (Fig. 4). A good agreement between predicted and observed values was obtained in both male (Fig. 4a, R² = 0.80) and female (Fig. 4c, R² = 0.59) patients from PLSR based on clinical parameters. The corresponding volcano plots identified a series of important clinical parameters, including Na, K, Mg, Cl, APTT, CRP, DD, WBC, LY, NG, FIB, blood platelet (BP), procalcitonin (PCT) and carbamide (CA) in male patients as well as P, Ca, Cl, APTT, WBC, RDW, diastolic pressure (DP), prothrombin time (PT) and hemoglobin (HGB) in female patients. Furthermore, regression analysis reveals that the concentrations of K (Fig. 5a, R = 0.47, P = 0.04) and Na (Fig. 5b, R = 0.60, P = 0.007) were significantly and positively correlated with the duration from positive to negative in male patients with non-severe COVID-19, while a negative association was obtained for FIB (Fig. 5c, R = -0.59, P = 0.006). Electrolyte imbalances were a common symptom in patients with COVID-19 by Lippi et al., who reported that K and Na were significantly lower in patients with severe COVID-19 [65]. However, our results indicate that non-severe COVID-19 patients with higher levels of K and Na may have a longer length of hospitalization in male patients. Of note, decreased FIB level can lead to hemorrhage. Although COVID-19 patients had been reported to show an increased level of FIB [66], higher FIB might reduce the duration from positive to negative in non-severe male patients. In female patients with non-severe COVID-19, however, we found that the duration from positive to negative was positively related with Cl (Fig. 5d, R = 0.48, P = 0.03) and negatively related with DP (Fig. 5e, R = -0.74, P < 0.001), P (Fig. 5f, R = -0.58, P = 0.009) and PT (Fig. 5g, R = -0.51, P = 0.02).

Based on metabolomics data, PLSR exhibited a better agreement between predicted and observed values in male patients relative to female patients (R², 0.75 vs. 0.59). A series of contributive metabolites for correlations were identified, such as cericropic acid B, 4-hydroxyproline, methyl beta-d-glucopyranoside, PGE1 alcohol, 13,14-dihydroxy-docosanoic acid, (+)-14-methyl palmitic acid, 17-hydroxy stearic acid and tetrahydroxycerotic in male patients (Fig. 4b), as well as carbanic acid, tyramine, alpha-d-glucose, leucine, PCE(O-16:1(9E)/0:0), PC(P-15:0/0:0), PC(O-8:0/0:0) and 11-deoxy-PGF1b in female patients (Fig. 4d). Subsequently, by regression analysis, we found that the duration from positive to negative in male patients with non-severe COVID-19 was positively correlated with 4-hydroxyproline (Fig. 6a, R = 0.50, P = 0.02) and negatively linked to fatty acids, including cericropic acid B (Fig. 6b, R = -0.52, P = 0.02) and (+)-14-methyl palmitic acid (Fig. 6c, R = -0.44, P = 0.05). As 4-hydroxyproline is a biomarker of collagen catabolism, higher circulating level of 4-hydroxyproline may indicate more serious tissue and organ injuries in COVID-19 patients [54,67]. Fatty acids have been shown to affect immune system [50]. Das suggested that administration of bioactive lipids could be beneficial to treat COVID-19 [68]. Moreover, in female patients, we found that high leucine level contributed to reduce the duration from positive to negative in non-severe COVID-19 patients (Fig. 6d, R = -0.49, P = 0.03). Leucine, a major component of branched-chain amino acids (BCAAs), plays an important role in activating protein synthesis and suppressing protein degradation [69] and also regulating immune functions [70]. In addition, virus infection can cause a decrease in BCAAs levels and then reduce albumin synthesis [71,72]. Therefore, leucine supplementation might be valuable for the treatment of non-severe COVID-19 especially in women.

4. Discussion

COVID-19 has been spreading rapidly around the world caused by SARS-CoV-2 in 2020, resulting in an unprecedented crisis in public health. Of note, men infected with SARS-CoV-2 have more severe disease and higher mortality than women due to sex differences in hormone [73], drug response [74] and immune system [20]. In the current study, we reveal that sex differences also exist for metabolic characteristics in plasma of non-severe COVID-19 patients during the recovery and rehabilitation process. In this process, metabolomics results demonstrate that the major metabolic alterations involved in fatty acids for men and glycerophosphocholines (GPCs) and carbohydrates for women. Many studies suggested a disrupted fatty acid metabolism after COVID-19 infection [14,15,23]. Moreover, fatty acids can affect lymphocytes and inflammation and thereby treat the viral infection [50,52]. Recently, Toelzer et al. reported that the essential free fatty acid linoleic acid (LA) binding stabilized the locked structure of SARS-CoV-2 spike protein and suppressed viral replication [75]. GPCs are derived from the breakdown of phosphatidylcholine (PTC), a major component of cellular membranes. We speculate that this metabolic pathway would be active during organ injury and repair in COVID-19 patients [54,67]. Additionally, carbohydrates as T cell-
Fig. 5. Linear regression analysis between the duration from positive to negative and clinical parameters in non-severe COVID-19 patients. Correlations of the duration from positive to negative with (a) the level of K, (b) the level of Na and (c) fibrinogen in male patients, and (d) the level of Cl, (e) DP, (f) the level of P and (g) prothrombin time in female patients. The correlation was considered to be statistically significant when $p < 0.05$.

Fig. 6. Linear regression analysis between the duration from positive to negative and metabolites in non-severe COVID-19 patients. Correlations of the duration from positive to negative with (a) 4-hydroxyproline, (b) ceriporic acid B and (c) (+)-14-methyl palmitic acid in male patients, and (d) leucine in female patients. The correlation was considered to be statistically significant when $p < 0.05$. 
activating antigens have been reported to play a key role in immune system functions [76]. Our data show that carbohydrates such as alpha-d-glucose, 1-kestose, D-ribose and D-mannose were positively correlated with NK cells in female patients but not in male patients. Collectively, attention has to be paid to the sex-specific impact of SARS-CoV-2 on host metabolism.

Metabolomics is becoming as a capable tool to discover metabolic biomarkers for disease diagnosis as well as prognostic and therapeutic evaluations [77]. Using metabolomics and lipidomics, potential metabolite panels have been identified in both serum and plasma to distinguish COVID-19 and assess disease severity [14,15]. Interestingly, here we proposed that metabolic profiling may contribute to predict the duration from positive to negative in non-severe COVID-19 patients, but men have a better predictive performance than women. Although this finding still needs to be further validated, prediction of the duration from positive to negative based on metabolic characteristics can be used to group patients for personalized treatment. Migaud et al. suggested that metabolomics phenotyping may predict antiviral drug efficacy in COVID-19 [78]. Metabolomics was also utilized to predict therapeutic efficacy such as chemotherapy [79], traditional Chinese medicine [80] and immunotherapy [81]. Therefore, we speculate that different metabolic environments in patients might influence drug efficacy and immune function [82], resulting in different durations from positive to negative in non-severe COVID-19 patients. Our results suggest a possible association between metabolic characteristics and the duration from positive to negative in non-severe COVID-19 patients, but sex differences in metabolic changes need to be considered.

5. Conclusion

In this study, we report an untargeted metabolomics analysis of plasma samples from both men and women with non-severe COVID-19 at acute period and after discharge. We reveal that the metabolic phenotypes of COVID-19 patients during the recovery and rehabilitation process were altered in a sex specific manner. In general, increased metabolic activities were detected in both male and female patients after discharge. We identified the major metabolic changes including fatty acids in men as well as GPCs and carbohydrates in women. Moreover, our results suggest that metabolic characteristics could be used to predict the duration from positive to negative in non-severe COVID-19 patients, but sex differences need to be paid attention. Several limitations and further works should be considered: (1) This study was based on a small Chinese cohort of COVID-19 patients in Wenzhou City of China, so we suggest that these findings still need to be validated from a larger longitudinal cohort and even from different racial and geographical cohorts; (2) Here we collected matched samples of male and female patients with non-severe COVID-19 at both acute period and after discharge, but a cohort of healthy men and women may need to be considered to examine sex-specific metabolic differences in the general population; (3) Metabolic data in the present study were not absolutely quantified, so more accurate quantification is required in clinical application.

6. Availability of data and materials

All data are present in the main text and the supplementary materials. LC-MS and GC–MS metabolomics data used in this study have been made publicly available in MetaboLights (ID: MTBLS2224). Additional data and materials related to this work can be requested from corresponding author.

CRediT authorship contribution statement

Hong Zheng: Methodology, Investigation, Formal analysis, Resources, Visualization, Writing - original draft, Writing - review & editing. Shengwei jin: Conceptualization, Investigation, Methodology, Project administration, Resources, Writing - review & editing. Ting Li: Data curation, Formal analysis, Investigation, Methodology, Writing - review & editing. Weiyang Ying: Investigation, Methodology, Resources, Writing - review & editing. Binyu ying: Investigation, Methodology, Resources, Writing - review & editing. Dong Chen: Investigation, Methodology, Resources, Writing - review & editing. Jie Ning: Investigation, Methodology, Writing - review & editing. Chanshan zheng: Investigation, Data curation, Writing - review & editing. Yuping li: Investigation, Methodology, Resources, Writing - review & editing. Chen Li: Investigation, Methodology, Writi, ng - review & editing. Chengshui Chen: Investigation, Resources, Writing - review & editing. Xiaokun li: Conceptualization, Supervision, Project administration, Funding acquisition, Writing - review & editing. Hongfeng Gao: Conceptualization, Supervision, Project administration, Funding acquisition, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank the Critical Care Group at Wenzhou Medical University for collecting plasma samples and all patients involved in this study. Additionally, we would like to give special thanks to all nurses and physicians in the world for confronting COVID-19 pandemic. This study was supported by the Key Research and Development Program of Zhejiang Province (No. 2020C03131 and No. 2019C03030), and the Ten-thousand Talents Program of Zhejiang Province (No. 2018R52052).

Authors’ contributions

XKL, SWJ, YPL, CSC and HCG contributed to design and supervise experiments. TL, WYY, BYY and DC contributed to collect clinical plasma samples. TL, DC and CFZ contributed to collect clinical information. JN, CL and HZ contributed to sample preparation and metabolomics analysis. HZ and HCG contributed to data analysis, result discussion and interpretation. HZ and HCG contributed to write the manuscript. All authors have read, revised and approved the final manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.csbj.2021.03.039.

References

[1] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;365(9923):507–13.
[2] Ghinaí I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet 2020;395(10184):1137–44.
[3] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan. China. JAMA. 2020;323(11):1061–9.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of COVID-19 in China. N Engl J Med 2020;382(18):1708–20.

Ai T, Yang Z, Hou H, Zhan C, Chen C, Li W, et al. (COVID-19) in China: a report of 49,369 cases. Radiology 2020;295:200–12.

Udagama B, Kadiresan P, Kozlowski HN, Malekajahani A, Osborne M, Li VY, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano 2020;14(4):3822–35.

Shen G, Kim NK, Baek SH, Choi M, Xu KB, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano 2020;14(4):5135–42.

Bastos ML, Tavares G, Abidi SK, Campbell JR, Harouz LP, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ 2020;370:m2516.

Xu Z, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020;117:21697–702.

Duan K, Liu B, Li C, Zhang H, Yu T, Qiu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020;117(19):9406–6.

Ben JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. PharmacoRes 2020;155:104743.

Yang X. Multitissue multitissue systems biology to dissect complex diseases. Trends Mol Med 2020;26:718–26.

Song LW, Lan SS, Liang S, Mao WJ, Wang SY, Tian H, et al. Omics-driven systems investigation of metabolic dysregulation in COVID-19 pathogenesis. Cell Metab 2020;32(2):188–202.

Shen B, Yi X, Sun Y, Yi X, Du J, Zhang C, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell Metab 2020;12(1):59–72.

Ayres JS. A metabolic hypothèse for the COVID-19 pandemic. Nature Metab 2020;2(7):572–85.

Klein SL, Dhalai S, Urin RL, Deshpande S, Sandberg K, Mouvai-Jervis F. Biochemical sex impact COVID-19 outcomes. PLoS Pathog 2020;16(6):1.e1008570.

Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 2020;11:1–13.

Qian J, Zhao L, Ye KZ, Li JX, Liu YL. Age-dependent gender differences of COVID-19 in mainland China: comparative study. Clin Infect Dis 2020;ciaa3883.

Li N, Li Y, Tiudong KG, Wang P, Israelov B, Lucas C, Klein SL, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature Metab 2020;2(7):572–85.

Cheudjeu A. Correlation of D-xylose with severity and morbidity-related factors in COVID-19. Nutr Metab Cardiovasc Dis 2020;30:102290.

Sbardella E, Tomlinson JW. Cortisol Metabolism as a Regulator of the Tissue-Immune Response. In: The Handbook of Pharmacology-Adrenal Axis in Health and Disease. Cham: Springer; 2017: p. 271–301.

White PC. Alterations of cortisol metabolism in human disorders. Horm Res Paediatr 2018;89(5):320–30.

Greeng B, Stockeck C, Condon A, Simon HU. Living and dying for inflammation: neutrophils, eosinophils, basophils. Trends Immunol 2013;34(8):398–409.

Vitte J, Dallio AB, Boumaza A, Lopez A, Michel M, Allardet-Servent J, et al. A granulocytic signature identifies COVID-19 and its severity. J Infect Dis 2020;222(12):1895–905.

Strohle A, Wolters M, Hahn A. Micronutrients at the interface between infection and inflammation ascorbic acid and calciferol. Part 1: general overview with a focus on ascorbic acid. Inflamm Allergy-Drug Targets. 2011;10:61–63.

Bozozet SM, Carr AC. The role of physiological vitamin C concentrations on key functions of neutrophils isolated from healthy individuals. Nutrients. 2019;11(6):1363.

Ananeva EA, Powell JD, Hutson SM. Leucine metabolism in T cell activation: mTOR signaling and beyond. Adv Nutr 2016;7(4):798–805.

Weigert A, Weis N, Brüne B. Regulation of macrophage function by sphingosine-1-phosphate. Immunology 2009;2009:419–10:748–60.

Joshi S, Kushi B, Roediger AM, Winiwarter C, Joshi S, Bock K, et al. SPHK2-generated SIP in CD11b+ macrophages blocks STING to suppress the inflammatory response of alveolar macrophages. Cell Rep 2020;30(12):4965–100.

Rui J, Révéred M, Schütter A, Casasnovas C, Villafoya F, Guiler A, et al. Altered glycolipid and glycerophospholipid signaling driving inflammatory cascades in adrenomyeloneuropathy. Human Mol Genet. 2015;24(24):6861–76.

Zhong C, Wang Y, Wang F, Wang Z, Lu Y, Xu Y, et al. Quantitative profiling of glycerophospholipids during mouse and human macrophage differentiation using targeted mass spectrometry. Sci Rep. 2017;7(1):1–13.

Ni M, Tian FB, Xiang DD, Yu B. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19. J Med Virol 2020;92:2560–6.

Yaqoob P, Calder PC. Fatty acids and immune function: new insights into the cutting edge between food and health. Br J Nutr 2007;98(S1):S41–5.

Johla CD, Grogg KR, Kirsch HP, Wiedmer C, Kaspary M, Kähler C, et al. Changes in immune responses that underlie COVID-19 disease outcomes. Nature Metab 2020;2(7):572–85.

McFarlin BK, Flynn MG, Stewart IK, Timmerman KL. Carbohydrate intake during cycling exercise increases natural killer cell responsiveness to IL-2. J Appl Physiol 2004;96(1):271–5.

McFarlin BK, Flynn MG, Hampton T. Carbohydrate consumption during cycling exercise increases in vitro NK cell responses to IL-2 and IFN-γ. Brain Behav Immun. 2007;21(2):202–4.

Zhong F, Yao M, Lin Z, Chen Y, Jiang H, Zeng M, et al. The effects of preoperative oral nutrition on the inflammation and human survival in patients with cancer. Cancer Nutr Metab. 2019;10:1796–807.

Luo X, Jiang Y, Liu H, Qiao F, Wang W, et al. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study. Signal Transduc Target Therapy. 2020;5:62.

Wang F, Nie J, Wang H, Zhao Q, Xiong D, Leng X, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis 2020;221(11):1762–9.

Sun L, Middleton DR, Wantuch PL, Ozdilek A, Avci FY. Carbohydrates as T-cell antigens with implications in health and disease. Glycobiology. 2016;26(10):1029–40.

McFarlin BK, Flynn MG, Stewart IK, Timmerman KL. Carbohydrate intake during endurance exercise increases natural killer cell responsiveness to IL-2. J Appl Physiol 2004;96(1):271–5.

Klein SL, Dhakal S, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 2020;11:1–13.

Qian J, Zhao L, Ye KZ, Li JX, Liu YL. Age-dependent gender differences of COVID-19 in mainland China: comparative study. Clin Infect Dis 2020;ciaa3883.

Thomas T, Stefanoni D, Reza JIA, Nemkov T, Bertolone L, Francis RO, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature Metab 2020;2(7):572–85.

Tsai NG, Tsai TH, Hung CH, Lai YC, Lai SW, et al. Immunological accuracy of COVID-19 patients using field-effect transistor-based biosensor. ACS Nano 2020;14(4):5135–42.
[64] Fisher BJ, Seropian IM, Kraskauskas D, Thakkar JN, Voelkel NF, Natarajan R. Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Crit Care Med. 2011;39(6):1454–60.

[65] Lippi G, South AM, Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem. 2020;57(3):262–5.

[66] Di Micco P, Russo V, Caramante N, Imparato M, Rodolfi S, Cardillo G, et al. Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian cohort. J Clin Med. 2020;9(5):1371.

[67] Laforge M, Elbim C, Frère C, Hémadi M, Massaad C, Nuss P, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol. 2020;20(9):515–6.

[68] Das UN. Bioactive lipids in COVID-19—further evidence. Arch Med Res 2020.

[69] Yoshizawa F. Regulation of protein synthesis by branched-chain amino acids in vivo. Biochem Biophys Res Commun. 2004;313(2):417–22.

[70] Kelly B, Pearce EL. Amino assets: how amino acids support immunity. Cell Metab. 2020;32:154–75.

[71] Wada Y, Takeda Y, Kuwahata M. Potential role of amino acid/protein nutrition and exercise in serum albumin redox state. Nutrients. 2018;10(1):17.

[72] Ambade V. Biochemical rationale for hypoalbuminemia in COVID-19 patients. J Med Virol. 2020. https://doi.org/10.1002/jmv.26542.

[73] Li Y, Jerkic M, Stafski AS, Zhang H. Molecular mechanisms of sex bias differences in COVID-19 mortality. Crit Care. 2020;24(1):1–6.

[74] Bischof E, Wolfe J, Klein SL. Clinical trials for COVID-19 should include sex as a variable. J Clin Invest. 2020;130:3350–2.

[75] Toelzer C, Gupta K, Yadav SK, Borucu U, Davidson AD, Williamson MK, et al. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. Science 2020;370(6517):725–30.

[76] Zhao H, Rains LN, Huang SCC. Carbohydrate and amino acid metabolism as hallmarks for innate immune cell activation and function. Cells. 2020;9(3):562.

[77] Jacob M, Lopata AL, Dasouki M, Abdel Rahman AM. Metabolomics toward personalized medicine. Mass Spectr Rev. 2019;38(3):221–38.

[78] Migaud M, Gandotra S, Chand HS, Gillespie MN, Thammickal VJ, Langley RJ. Metabolomics to predict antiviral drug efficacy in COVID-19. Am J Respir Cell Mol Biol. 2020;63(3):396–8.

[79] Tian Y, Wang Z, Liu X, Duan J, Feng G, Yin Y, et al. Prediction of chemotherapeutic efficacy in non–small cell lung cancer by serum metabolomic profiling. Clin Cancer Res. 2018;24(9):2100–9.

[80] Zhang AH, Sun H, Yan GL, Han Y, Zhao QQ, Wang XJ. Chinnedomics: a powerful approach integrating metabolomics with serum pharmacochemistry to evaluate the efficacy of traditional Chinese medicine. Engineering. 2019;5(1):60–8.

[81] Shi HY, Pan C, Ma TT, Chen YL, Yan WJ, Liu JG, et al. Clinical efficacy evaluation of 1-year subcutaneous immunotherapy for Artemisia sieversiana pollen allergic rhinitis by serum metabolomics. Front Pharmacol. 2020;11:305.

[82] Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ. Antibiotic-induced changes to the host metabolic environment inhibit drug efficacy and alter immune function. Cell Host Microbe. 2017;22(6):757–65.